13.73
price up icon10.55%   1.31
after-market After Hours: 13.69 -0.04 -0.29%
loading
Lyell Immunopharma Inc stock is traded at $13.73, with a volume of 255.15K. It is up +10.55% in the last 24 hours and up +53.58% over the past month. Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$12.42
Open:
$12.59
24h Volume:
255.15K
Relative Volume:
1.89
Market Cap:
$203.31M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-17.38
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+44.68%
1M Performance:
+53.58%
6M Performance:
+12.63%
1Y Performance:
-58.14%
1-Day Range:
Value
$12.59
$14.18
1-Week Range:
Value
$9.56
$14.18
52-Week Range:
Value
$7.65
$34.40

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Name
Lyell Immunopharma Inc
Name
Phone
650 695-0677
Name
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Employee
300
Name
Twitter
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
LYEL's Discussions on Twitter

Compare LYEL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LYEL
Lyell Immunopharma Inc
13.73 230.82M 54,000 -210.26M -159.01M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-30-24 Downgrade BofA Securities Buy → Underperform
Jun-27-24 Downgrade H.C. Wainwright Buy → Neutral
Aug-28-23 Downgrade JP Morgan Overweight → Neutral
Nov-14-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-11-22 Downgrade Goldman Buy → Neutral
Oct-17-22 Initiated H.C. Wainwright Buy
Jul-12-21 Initiated BofA Securities Buy
Jul-12-21 Initiated Goldman Buy
Jul-12-21 Initiated JP Morgan Overweight
Jul-12-21 Initiated Morgan Stanley Overweight
View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

pulisher
Jul 28, 2025

What is the dividend policy of Lyell Immunopharma Inc. stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How to use a screener to detect Lyell Immunopharma Inc. breakouts Free Technical Entry Strategy for Beginners - Newser

Jul 28, 2025
pulisher
Jul 27, 2025

What catalysts could drive Lyell Immunopharma Inc. stock higher in 2025Extraordinary profit generation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is Lyell Immunopharma Inc. stock compared to the marketInvest confidently with expert support - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Sectors Driving Future Growth for Lyell Immunopharma Inc. StockHigh Potential Safe Trades - Newser

Jul 27, 2025
pulisher
Jul 26, 2025

What makes Lyell Immunopharma Inc. stock price move sharplyEarly Breakout Tracker - Newser

Jul 26, 2025
pulisher
Jul 25, 2025

What drives Lyell Immunopharma Inc. stock priceExceptional financial outcomes - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma $100M Deal: Can Buyers Hold the Stock After 20% Surge? - FXLeaders

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma (LYEL) Stock Soars Following Private Placement Announcement - FinancialBuzz.com

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma's $100M Private Placement: How Milestone-Driven Capital Raises De-Risk Biotechs and Create Asymmetric Upside - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

What makes Lyell Immunopharma Inc. stock attractive to long term investorsExplosive capital appreciation - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma announces up to $100M equity private placement - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma Taps Investors For $100 Million In New Funding - Finimize

Jul 25, 2025
pulisher
Jul 25, 2025

Is Lyell Immunopharma Inc. a good long term investmentBreakthrough profits - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma secures up to $100 million in private placement By Investing.com - Investing.com South Africa

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma Secures $100 Million in Private Placement - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Why Lyell Immunopharma Inc. stock attracts strong analyst attentionROI Focused Stock Calls - Newser

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewswire

Jul 25, 2025
pulisher
Jul 25, 2025

Lyell Immunopharma Raises $100M to Advance Breakthrough Cancer Cell Therapy Through Pivotal Trials - Stock Titan

Jul 25, 2025
pulisher
Jul 25, 2025

Is Lyell Immunopharma Inc. stock overhyped or has real potentialOutstanding capital returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Lyell Immunopharma Inc. stockMarket-leading capital gains - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

Positive week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional investors who lost 70% over the past year - simplywall.st

Jul 23, 2025
pulisher
Jul 22, 2025

Lyell Immunopharma Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lyell Immunopharma's LYL314: A High-Risk, High-Reward Catalyst in the CAR T-Cell Space - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement (LYEL) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 20, 2025

Lyell Immunopharma registers 625,000 shares for resale - MSN

Jul 20, 2025

Lyell Immunopharma Inc Stock (LYEL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):